Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nasdaq  >  Celgene    CELG   

CELGENE

(CELG)
  Report
SummaryQuotesChartsNewsCompanyFinancials 
News SummaryMost relevantAll newsPress ReleasesOfficial PublicationsSector news
Communiqués de presse de la société CELGENE
05/28BX Swiss AG receives approval from FINMA as a Prospectus Review Office
TE
2019CELGENE : Announces Plans to Transfer Listing of Celgene's Contingent Value Righ..
AQ
2019CELGENE : Bonney michael w
PU
2019CELGENE : Casey michael d
PU
2019CELGENE : Friedman michael a
PU
2019CELGENE : Cox carrie smith
PU
2019CELGENE : Loughlin james j
PU
2019CELGENE : Haller julia a
PU
2019CELGENE : Reicin alise
PU
2019CELGENE : Curran terrie
PU
2019CELGENE : Biller jonathan
PU
2019CELGENE : Alles mark j
PU
2019CELGENE : Elkins david v
PU
2019CELGENE : Ahmed nadim
PU
2019CELGENE : Vessey rupert
PU
2019CELGENE : Bishop hans edgar
PU
2019CELGENE : Barker richard w
PU
2019CELGENE : Hall patricia hemingway
PU
2019CELGENE : Weiland john h
PU
2019CELGENE : Mario ernest
PU
2019CELGENE : Current report filing
PU
2019CELGENE CORP /DE/ : Termination of a Material Definitive Agreement, Completion o..
AQ
2019CELGENE : Notification filed by National Security Exchange to report the removal..
PU
2019CELGENE : Announces Plans to Transfer Listing of Celgene's Contingent Value Righ..
BU
2019Bristol-Myers Squibb Receives Clearance from U.S. Federal Trade Commission fo..
AQ
2019BRISTOL-MYERS SQUIBB COMPANY : Announces It Expects No Further Extension of the ..
AQ
2019CELGENE : Receives CHMP Positive Opinion for REVLIMID® (lenalidomide) in Combina..
BU
2019SKYHAWK THERAPEUTICS : Announces a Second Multi-Target Collaboration Agreement w..
PR
2019CELGENE CORPORATION : - FDA Approves REBLOZYL for the Treatment of Anemia in Adu..
AQ
2019CELGENE : Cox carrie smith
PU
2019CELGENE : to Present New and Updated Data on Key Hematology Pipeline Therapies a..
BU
2019CELGENE : Ahmed nadim
PU
2019CELGENE : Reicin alise
PU
2019CELGENE : Curran terrie
PU
2019CELGENE : Vessey rupert
PU
2019CELGENE : Biller jonathan
PU
2019BRISTOL-MYERS SQUIBB COMPANY : Announces Extension of the Expiration Date for Ex..
AQ
2019CELGENE : DE/ Management's Discussion and Analysis of Financial Condition and Re..
AQ
2019CELGENE : 3Q Earnings Snapshot
AQ
2019CELGENE CORP /DE/ : Results of Operations and Financial Condition, Financial Sta..
AQ
2019CELGENE : Reports Third Quarter 2019 Operating and Financial Results
BU
2019BRISTOL MYERS SQUIBB : Announces Extension of the Expiration Date for Exchange O..
AQ
2019CELGENE : and the Multiple Sclerosis Association of America Take the MS MindShif..
BU
2019CELGENE CORPORATION : Names Second Round of Celgene Cancer Care Links Program Gr..
AQ
2019CELGENE CORPORATION : Names Second Round of Celgene Cancer Care Links™ Pro..
BU
2019CELGENE : Announces Phase 3 QUAZAR® AML-001 Study of CC-486 as Maintenance Thera..
BU
2019CELGENE : Data from Ozanimod Clinical Development Program in Relapsing Forms of ..
BU
2019CELGENE : Immatics and Celgene Enter Strategic Collaboration to Develop Novel Ad..
AQ
2019Bristol-Myers Squibb Announces Agreement between Celgene and Amgen to Divest ..
AQ
2019Amgen to Acquire Otezla for $13.4 Billion in Cash, or Approximately $11.2 Bil..
AQ
2019Celgene and SRC Energy post gains while Pitney Bowes dips
AQ
2019AMGEN : to spend $13.4B on Celgene psoriasis drug Otezla
AQ
2019CELGENE CORP /DE/ : Entry into a Material Definitive Agreement, Financial Statem..
AQ
2019CELGENE CORPORATION : - U.S. FDA Approves INREBIC as First New Treatment in Near..
AQ
2019CELGENE : U.S. FDA Approves INREBIC® (Fedratinib) as First New Treatment in Near..
BU
2019CELGENE : DE/ Management's Discussion and Analysis of Financial Condition and Re..
AQ
2019CELGENE : 2Q Earnings Snapshot
AQ
2019CELGENE CORP /DE/ : Results of Operations and Financial Condition, Financial Sta..
AQ
2019CELGENE : Reports Second Quarter 2019 Operating and Financial Results
BU
2019CELGENE : and the Multiple Sclerosis Association of America Bring MS MindShift I..
BU
2019CELGENE : FDA Approves OTEZLA® (apremilast) for the Treatment of Oral Ulcers Ass..
BU
2019BRISTOL-MYERS SQUIBB COMPANY : Announces Extension of the Expiration Date for Ex..
AQ
2019MEREO BIOPHARMA : Celgene Terminates Mereo Collaboration And Will Not Licence Et..
AQ
2019Mereo BioPharma Group plc - Update on Etigilimab Partnership
AQ
2019LEOPLUS USA WINS LYFEBULB-CELGENE 20 : An Innovation Challenge"
PR
2019Mereo BioPharma Group plc (Mereo or the Company or the Group) Update on Etigi..
AQ
2019CELGENE : US FDA and EMA Accept Applications for Ozanimod for the Treatment of R..
BU
2019EVOTEC : and Celgene further expand iPSC collaboration including new cell type
AQ
2019CELGENE : Updated Analysis of JAKARTA2 Fedratinib Study Shows Clinically Meaning..
BU
2019CELGENE : Presents Data from a Phase 1/2 Clinical Study of Iberdomide in Combina..
BU
2019CELGENE : FDA Approves REVLIMID® (Lenalidomide) In Combination With Rituximab Fo..
BU
2019CELGENE : and the Multiple Sclerosis Association of America Team Up to Launch MS..
BU
2019CELGENE : Receives European Commission Approvals for REVLIMID® (lenalidomide) an..
BU
2019CELGENE : to Highlight New and Updated Hematology and Oncology Clinical Data at ..
BU
2019CELGENE CORPORATION : Announces POMALYST® Granted Breakthrough Therapy Designati..
BU
1  2  3  4  5  6  7  8  9  10Next